Recent Advances in $^{19}$Fluorine Magnetic Resonance Imaging with Perfluorocarbon Emulsions

Anne H. Schmieder$^1$, Shelton D. Caruthers$^{2,3}$, Jochen Keupp$^4$, Samuel A. Wickline$^1$, and Gregory M. Lanza$^1,*$

$^1$Division of Cardiology, Washington University School of Medical, St. Louis, MO 63110, USA
$^2$Toshiba Medical Research Institute USA, Inc., Cleveland, OH 44143, USA
$^3$Department of Biomedical Engineering, Washington University, St. Louis, MO 63130, USA
$^4$Philips Research Hamburg, Hamburg 22335, Germany

Abstract

The research roots of $^{19}$fluorine ($^{19}$F) magnetic resonance imaging (MRI) date back over 35 years. Over that time span, $^1$H imaging flourished and was adopted worldwide with an endless array of applications and imaging approaches, making magnetic resonance an indispensable pillar of biomedical diagnostic imaging. For many years during this timeframe, $^{19}$F imaging research continued at a slow pace as the various attributes of the technique were explored. However, over the last decade and particularly the last several years, the pace and clinical relevance of $^{19}$F imaging has exploded. In part, this is due to advances in MRI instrumentation, $^{19}$F/$^1$H coil designs, and ultrafast pulse sequence development for both preclinical and clinical scanners. These achievements, coupled with interest in the molecular imaging of anatomy and physiology, and combined with a cadre of innovative agents, have brought the concept of $^{19}$F into early clinical evaluation. In this review, we attempt to provide a slice of this rich history of research and development, with a particular focus on liquid perfluorocarbon compound-based agents.

Keywords

fluorine; magnetic resonance imaging (MRI); dual-tuned coil; perfluorocarbon; angiogenesis; cell labeling

1 Introduction

Although hydrogen-based ($^1$H) magnetic resonance imaging (MRI) predominates over the cadre of magnetic resonance (MR) techniques employed clinically, renewed interest in $^{19}$fluorine ($^{19}$F) MRI continues to increase, particularly for molecular imaging.
applications using perfluorocarbons (PFCs) as a fluorine source. MR fluorine spectroscopy and imaging dates back to 1977, a time when human \(^1\)H MRI was in its infancy \[1\]. Several investigators contributed to the early technical foundation of \(^1\)H imaging \[2–7\].

1.1 Why \(^{19}\)fluorine?
Interest in \(^{19}\)F nuclei imaging reflects its potential as a quantitative MRI contrast agent. \(^{19}\)F has 100% natural abundance, a spin of 1/2, and a gyromagnetic ratio of 40.08 MHz·T\(^{-1}\) (slightly lower than the 42.58 MHz·T\(^{-1}\) of \(^1\)H), resulting in 83% of the sensitivity of \(^1\)H \[8, 9\]. With seven outer-shell electrons, \(^{19}\)F chemical shifts (CSs) are more sensitive to the local environment than \(^1\)H with its single electron. Indeed, the spectroscopic signatures of \(^{19}\)F compounds can vary over a range more than 200 ppm \[10, 11\], offering the potential for definitive identification of many compounds even at lower clinical field strengths. Although soft body tissues, which contain 55%–75% water, contribute a substantial mobile \(^1\)H signal, fluorine is essentially absent from soft tissues and is only found immobilized in bones or teeth, where its very short spin-spin relaxation time (T2) renders \(^{19}\)F virtually invisible to conventional MR techniques. \(^{19}\)F MRI of high-density exogenous fluorine compounds accumulating at target sites offers high contrast-to-noise ratios (CNRs) and improved quantification potential. Furthermore, the negligible \(^{19}\)F background obviates the use of the serial pre-/post-contrast image comparisons that are requisite for differentiating superparamagnetic (e.g., iron oxide) or paramagnetic metal (e.g., gadolinium) contrast from the background in most molecular imaging studies.

1.2 Perfluorocarbons (PFCs)
PFC nanoparticles are 98% PFC by volume, which for perfluoroctylbromide (PFOB, 1.98 g·mL\(^{-1}\), 498 Daltons) equates to a fluorine concentration of approximately 100 mol·L\(^{-1}\) \[12\]. PFC nanoparticles are distinctly different from other oil-based emulsions by virtue of the physical-chemical properties of fluorine, the most electronegative of all elements, and the unique properties of C—F bonds \[13\]. The fluorine-substituted hydrogen in perfluorochemicals creates bulkier, stiffer compounds that typically adopt a helical conformation with the molecules chemically distinct but often closely intertwined \[13\]. The C—F bond is chemically and thermally stable and its dense electron cloud creates a barrier to encroachment by other chemical reagents, rendering it virtually non-chemically reactive \[13\]. The resultant large surface area combined with the low polarizability of the fluorinated chains enhances hydrophobicity. Interestingly, PFCs are both hydrophobic and lipophobic!

The biocompatibility of liquid fluorocarbons is well documented in numerous preclinical animal studies. Even at large doses, most fluorocarbons are innocuous and physiologically inactive. No toxicity, carcinogenicity, mutagenicity, or teratogenicity effects have been reported for pure fluorocarbons within the 460–520 MW range. PFCs have tissue half-life residencies ranging from 4 days for PFOB up to 65 days for perfluorotripropylamine, and are not metabolized; rather, they are slowly reintroduced to the circulation in dissolved form by lipid carriers and expelled through the lungs. However, increased pulmonary residual volumes from expired PFC, which is denser than air, and reduced pulmonary compliance, is noted with blood-transfusion-level dosages, particularly with some early-generation PFC emulsions in rabbits, swine, and macaques, although not in mice, dogs, or humans \[13–15\].
Similarly, PFC nanoparticles are cleared through the monocyte-phagocyte system (MPS), previously referred to as the reticulo-endothelial system (RES). Repeated high dosages of PFCs by these cells can lead to the release of macrophage cytokines, resulting in flu-like symptoms [12]. Moreover, acute engorgement of the liver with PFC nanoparticles due to a large-volume infusion or repeated high-volume dosing can result in the transient physical compression of tissue with mild hepatocellular damage, resulting in reversible elevations in serum transaminases [16].

Furthermore, it must be recognized that in rodents, nanoparticles such as PFC nanoparticles can pass rapidly and directly into the biliary system, where they flow into the small intestine [17, 18]. In non-rodent species, such as rabbits or humans, this rapid bioelimination is not present [19]. Thus, pharmacokinetics, biodistribution, and the safety of PFC nanoparticles will differ significantly between rodent and non-rodent species, affecting the dosages administered to compensate for the loss or the assessments of dose-safety margins of particles and their contrast or therapeutic payloads [18].

Early preclinical and later clinical research with PFCs involved liquid breathing, recognizing the high oxygen-dissolving capacity of PFCs and the need to address surfactant deficiencies in preterm babies [20–25]. Although it was an interesting and effective application, this use of PFCs was rapidly superseded by the development of alternative surfactant replacement technologies. However, the oxygen-dissolving capacity of PFC emulsions was not forgotten, and efforts to develop these agents as artificial blood substitutes were pursued with limited success.

Fluosol-DA (Green Cross, Japan) was the first PFC emulsion approved for blood replacement, but it was associated with significant hemodynamic compromise related mostly to the choice of surfactant [26–32]. A similar particle, Fluosol-43, was later developed, substituting an albumin surfactant to counter the unstable hemodynamic issues. Fluosol-DA was composed of a mixture of perfluorodecalin (PFD) and perfluorotributylamine, which are fluorine compounds with complicated MR spectra. From an MR cell-tracking perspective, PFD offers limited imaging or spectroscopy potential, even with today’s more highly refined instruments and techniques [33, 34]. The next generation of PFCs pursued clinically for artificial blood substitutes were PFOB (Alliance Pharmaceuticals) and perfluorodichloro-octane (PFDCO, HemaGen/PFC, Inc.). These fluoro-compounds reduced pulmonary gas stacking and decreased the time for PFC bioelimination from tissues. These second-generation PFC-based blood substitutes utilized phospholipid surfactants for better biocompatibility, better oxygen-dissolving capacity, and fewer significant side effects, improved bioelimination rates, and were amenable to large-scale commercial production. The oxygen dissolved in the PFC liquid was easily extracted by oxygen-deprived tissues. However, the oxygen-loading capacity of PFCs is linearly related to the partial pressure of oxygen in equilibrium with the emulsion. PFCs demonstrate a nearly flat, linear oxygen dissociation curve in contrast to the sigmoidal dissociation curve of hemoglobin. As a result, most of the oxygen dissolved in the PFC is released in the high-pressure atmosphere of the arteries, with little oxygen being available for the capillary network where the partial pressure of oxygen is lower and the need is greatest. PFC products essentially failed clinically as blood substitutes.
During this time, Dr. Robert Mattrey, working with the Alliance PFOB emulsion platform, conducted early studies to determine whether these particles offered clinical imaging potential with ultrasound (US), computed tomography (CT), and MRI [35–44]. Although much of this work centered upon liquid PFC nanoparticles for US and CT and required large volumes of materials to provide blood pool contrast, only the use of PFOB emulsions for gastrointestinal (GI) contrast (negative contrast) with $^1$H MRI gained traction. In this application, PFOB particles offered significant imaging and procedural advantages over standard barium contrast studies, but at a higher cost. The much lower cost of using barium for GI imaging won out.

2 MRI with PFC emulsions

The stability and significant prior human experience with PFOB offered a unique modifiable nanoparticulate theranostic platform technology that has been extensively exploited in a variety of medical applications by our laboratory, both alone and in collaboration with many others [16, 45–79]. For $^1$H MRI, PFC nanoparticles provided a stable platform for high payloads of lipophilic gadolinium chelates to enhance targeted MR molecular imaging. However, with increasing concerns regarding gadolinium-induced nephrogenic systemic fibrosis and acute complement activation noted in clinical trials [80–82], $^{19}$F imaging with targeted PFOB nanoparticles at 3 T was reconsidered in order to address these significant unmet clinical needs.

More recently, MR cell tracking with fluorocarbon labeling was pursued as an alternative to more commonly used iron oxide nanoparticles [83–90]. These investigators brought increased attention to the use of cyclic perfluoro-15-crown-5-ether (PFCE) and linear perfluoropolyether (PFPE) molecules that have repeating —CF$_2$CF$_2$O— units for improved $^{19}$F signal-to-noise ratio (SNR) and detectability [63, 91–101]. When used for systemically targeted molecular imaging, the heavy accumulation of PFCE in the liver and spleen combined with its very prolonged biological clearance rate presented a noteworthy human safety barrier to clinical translation. In the context of cell tracking, the PFC emulsion particles are internalized by cells ex vivo then administered, often locally by image-guided injection, and the vast excess of PFC particles associated with systemically injected PFC emulsions is avoided. In this context, the prolonged duration of these compounds might be considered an asset for the serial cell tracking over a more prolonged timeframe. More recently, PFPE has gathered increased interest with the advent of cell tracking, with its > 40 chemically equivalent fluorine atoms simplifying the $^{19}$F nuclear magnetic resonance (NMR) spectra, and a small T1/T2 ratio. Unusually for a PFC, the end-groups may be chemically functionalized, such as with dyes [92, 102].

3 $^{19}$F detectability with MR

Since the concentrations of PFCs employed in biological systems are low, the typical $^{19}$F imaging SNR is low compared with that of $^1$H MRI. While some applications do administer large volumes of highly fluorinated fluoro-compounds and produce effective $^{19}$F images, high doses (more than 1–5 g/kg for PFCs) may be limited in humans by the aforementioned safety concerns [12]. To date, magnetic resonance spectroscopy (MRS) studies in a whole-
body scanner suggest a minimum detectable limit of $^{19}$F at 1.5 T of about 30 μmol·g$^{-1}$ wet weight in a volume of about 33 mL in 6 min, based on surface coil measurements following the infusion of 5-fluorouracil (5-FU) chemotherapy [103]. At higher field strengths, spectroscopic 5-FU quantification of about 5 nmol·g$^{-1}$ in 0.5–1.2 g samples at 11.7 T and one-hour data acquisition is possible [104].

PFCE contains 20 resonant equivalent $^{19}$F nuclei that enrich the signal to allow 30 μmol·g$^{-1}$ wet weight detection in a 4-min scan time in a volume of 60 μL $in vivo$ at 9.4 T [67]. Related measurements by Partlow et al. [63] suggested a detection limit (SNR > 3) of approximately 2000 cells for PFCE, approximately 10 000 cells for PFOB-labeled cells for $in vitro$ with $^{19}$F MRS (11.7 T), and approximately 6000 PFCE-labeled cells/voxel $in vitro$ with $^{19}$F MRI (11.7 T). For imaging at 1.5 T, the $in situ$ localized injection of 4 million CE-labeled stem cells produced a strong fluorine signal. Quantification of PFC intracellular content following 12-hour cellular co-incubation without adjunctive transfection agents reached up to 3 pmol per cell. Moreover, the r1 contrast sensitivity of PFCE, like that of other PFCs, improves with increasing magnetic field strength, which has proved advantageous, as clinical MR instrumentation has increased from 3 T to 7 T and above. However, it also means that non- or off-target $^{19}$F noise has become proportionately more prominent. Clearly, PFC particles markedly enhance the local fluorine concentration to permit cell tracking or targeted molecular imaging studies.

Further $^{19}$F signal detectability at clinical field strengths (3 T and below) can be achieved by incorporating a relaxation-modifying agent, lipid-anchored-gadolinium (Gd$^{3+}$), into the outer surfactant layer surrounding PFC nanoparticles. Neubauer et al. [105] showed that the addition of lanthanide imparted a four-fold augmentation of the $^{19}$F signal from 200 nm PFC nanoparticles at 1.5 T. This was reflected as a 125% increase in contrast signal when the nanoparticles were targeted to fibrin clots $in vitro$. These investigators also noted that modifications of the Gd$^{3+}$ surface concentration and the lanthanide metal position relative to the particle surface could be used to tailor or eliminate the $^{19}$F benefit. This concept was corroborated by Harvey et al. [106], and then further explored by de Vries et al. [107]. de Vries et al. studied this concept using three different PFC emulsions at five magnetic field strengths. Using PFCE and three lipophilic chelates (Gd$^{3+}$ DOTA–DSPE, Gd$^{3+}$ DOTA–C6–DSPE, and Gd$^{3+}$ DTPA–BSA), they noted that Gd$^{3+}$ DTPA–BSA, which positions the lanthanide metal close to the PFC core, had a strong influence on $^{19}$F R1 compared with Gd$^{3+}$ DOTA–DSPE and Gd$^{3+}$ DOTA–C6–DSPE, which position the metal further into the surrounding water and away from the PFC core. At typical clinical field strengths (1.5–3.0 T), Gd$^{3+}$ DTPA–BSA inclusion favorably influenced $^{19}$F R1, but at higher field strengths (6.3–14 T), supplemental Gd$^{3+}$ did not lead to an improvement and could adversely increase $^{19}$F R2. Because $^{19}$F r1 relaxivity inherently improves with increasing field strengths, as used in preclinical animal scanners, the need to further augment the $^{19}$F signal with a lanthanide has diminished.

4 MR $^{19}$F coils

MRI of fluorinated contrast agents is challenged by low sensitivity, especially at clinical field strengths (3 T or below). $^{19}$F molecular imaging has been enabled by the effective
concentration of PFC probes to specific pathological sites via ligand-directed homing; the image-guided local injection of cells enriched with high PFC payloads into regions of interest; the use of single resonance $^{19}$F molecules; and the correction of CS artifacts [108], ultrafast MR [109–111], and compressed sensing [100] acquisition techniques for multispectral agents. However, clear improvements in radiofrequency (RF) coil design, and particularly the development of dual $^{19}$F/$^1$H imaging, have emerged as essential advancements to $^{19}$F imaging technology [73, 112–118].

Single-frequency-mode RF coils for $^{19}$F/$^1$H MRI are typically employed where the coil frequency is tuned to either $^{19}$F or $^1$H frequency to maximize the SNR. This approach requires time and potentially leads to coil motion and displacement that can complicate later $^{19}$F/$^1$H image co-registration. Two-coil approaches such as a volume coil for $^1$H imaging and a surface coil for $^{19}$F imaging can be effective for acquiring the individual signals, but their inherently different sensitivity patterns can lead to image discordance when the two frequency datasets are combined. Auto-tuned RF coils that use an external computer program emerged to switch resonant frequency are an option in some of the more expensive imaging systems, but these come with increased complexity [119]. Overall, single-frequency-mode RF coils for $^{19}$F/$^1$H MRI imaging are challenged to overcome several issues: diminished SNR, differential $B_1$ field inhomogeneity artifacts, and co-registration error of $^1$H/$^{19}$F signals.

To address these challenges, dual $^{19}$F/$^1$H coils were explored. Dual-frequency coils for two well-separated resonant frequencies such as $^1$H (42.58 MHz·T$^{-1}$) and $^{13}$C (10.71 MHz·T$^{-1}$) are typically designed utilizing shunting and multiple pole methods. Unfortunately, this classic approach is less suited for $^{19}$F/$^1$H MRI coils where the $^{19}$F gyromagnetic ratio of 40.08 MHz·T$^{-1}$ is close to that of $^1$H. One design approach considered a universal matching circuit via multiport input for multi-frequency. Another tactic considered close dual-frequency coil strategies based on the special resonant property of a birdcage resonator, particularly for preclinical scanners, wherein two crossed cages or two different modes of a birdcage are used to achieve the double resonance.

A more progressive approach was proposed by Hockett et al. [118], who employed a tuned and matched dual-frequency coil that used an enclosed solenoid geometry reported by researchers at Philips Research [120], but that was modified to meet the operational constraints imposed by the size and access requirements of an arthritic rabbit-knee model (Figures 1 and 2). This design extended the dual-frequency coil simultaneous image concept to include a double-tuned circuit with an input parallel resistor, inductor, and capacitor (RLC) auxiliary resonant circuit in series with an open-coil design based on a geometry proposed by Ballon et al. [121] and Jin et al. [122]. The open-coil design allowed a cylindrical shape and multiple loops, with current steering similar to a birdcage design, in order to provide a larger coil volume with enhanced field uniformity while maintaining adequate sensitivity to support transmit-and-receive imaging of the rabbit knee at both nuclei at 3 T. A unique strength of this design was its ability to image both anatomy and exogenous contrast truly simultaneously, eliminating the chance for image registration problems while maximizing throughput. Subsequently, Hu et al. [117] extended the coupled resonator model approach of Hockett et al. [118] to a universal design technique affording the fabrication...
of $^{19}$F/$^1$H dual-frequency coils in diverse configurations. For these approaches, the matching required for a dual-frequency coil to function properly with the differential impedances at the two resonant frequencies was a critical design challenge. Hockett et al. [118] and later Hu et al. [117] showed that a series capacitive matching network was theoretically effective in matching the coupled resonator to 50 $\Omega$ for both $^{19}$F and $^1$H frequencies. Hu et al. implemented this $^{19}$F/$^1$H dual-frequency birdcage RF coil for in vivo imaging at 4.7 T to illustrate its feasibility (Figure 3). They demonstrated rapid acquisitions with a high SNR saddle coil using an actively decoupled surface coil on $^{19}$F frequency for both $^{19}$F and $^1$H signals. They achieved homogeneous excitation with high sensitivity for $^{19}$F MRI, while retaining sufficient SNR from $^1$H signal for anatomy images.

Recently, $^{19}$F/$^1$H dual-tuned coils were extended by Ji et al. in Niendorf’s lab for human application at 7.0 T [116]. A modular eight-channel $^{19}$F/$^1$H transceiver RF coil array for the human knee was designed and tested that enabled $^{19}$F localization of an epicutanously applied $^{13}$F-NSAID ointment. In-plane spatial resolution was very high (1.5 mm × 1.5 mm) and acquisition was rapid—about three minutes of scan time. This eight-channel high-sensitivity array was adaptably positioned close to the patient and allowed for transmit field ($B_0^+$) shaping by adjusting the magnitude and phase of different channels to minimize inhomogeneity at this ultrahigh frequency.

5 MR $^{19}$F PFC imaging

While high specificity for $^{19}$F detection comes from the virtual absence of background $^{19}$F in the body, this same paucity of signal complicates image formation optimization and motion assessments. A typical MR scanner automatically performs operator-independent preparation steps to determine the appropriate power setting for a desired flip angle, RF coil, and patient combination. Such power optimization requires rapid detection of a robust signal. The low SNR of $^{19}$F images precludes this essential power optimization step for single $^{19}$F nuclei coils.

For better simultaneous $^{19}$F/$^1$H MRI on a clinical 3 T scanner, Keupp et al. [114] devised a novel architecture with modified spectrometers and software for concurrent dual-nuclei MRI, while other components of the scanner (e.g., the gradient system and magnet) remained unchanged. Separate transmitter and receiver devices for the non-proton nucleus were added in order to achieve simultaneous excitation of $^1$H and $^{19}$F nuclei. Waveforms for the prescribed RF pulses were created independently for each nucleus and fed simultaneously into the RF amplifier. With this instrumentation in particular, power optimization of the $^{19}$F/$^1$H dual-tuned coils for a specific patient can be performed by using the rich $^1$H signal and then applying the results for both $^1$H and $^{19}$F imaging [123]. The spatial inhomogeneity of RF coil sensitivity (which is present in all MRI coils, and is often corrected “behind the scenes” in clinical scanners) can be applied from the $^1$H to the $^{19}$F channel in these dual-tuned coils [73]. For absolute quantitation of the $^{19}$F signal, as for serial clinical molecular imaging, these calibration and correction steps will be required.

The scan times for $^1$H scans can be quite low due to the abundance of tissue water, whereas the paucity of the $^{19}$F signal must be compensated with extended signal averaging. This
makes the acquisition prone to motion artifacts arising from anatomical and patient motion movement, which lead to signal degradation due to blurring and $^{19}$F/$^1$H image misregistration. Simultaneous readout of both $^1$H and $^{19}$F affords motion artifact correction using the $^1$H image data that is then applied to the $^{19}$F images [114]. With 3D radial k-space filling, under-sampling $^1$H images (i.e., reconstructed at a much higher temporal resolution than the full $^{19}$F k-space) allow data motion correction over prolonged image-acquisition times, which increases $^{19}$F SNR and quantification accuracy [114].

Fluorine detection is technically challenged by compounds with short T2 relaxation times varying across their spectral peaks and CS artifacts. To address these issues with multinuclear MR, Mastropietro et al. [124] optimized the sequence parameters of fast spin echo (FSE/RARE). Although the approach was effective for some $^{19}$F molecules, compounds with unique spectral properties required individual parameter tuning to the local environment. For multispectral compounds such as PFOB, common $^{19}$F resonant groups can be selected for acquisition at the expense of the diminished SNR efficiency incurred by ignoring other spectral lines of the compound. To capture full spectral information, a technique of chemical species separation by iterative decomposition with echo asymmetry and least-squares estimation (IDEAL) was studied, but this technique necessitates complex $\delta B_0$ correction [125, 126]. To capture signal from all PFOB spins, echo time (TE) encoding with relaxation correction has been implemented [127] in addition to pulse-phase encoding (PPE) [128]. Interestingly, chemical-shift-independent techniques like fluorine ultrafast turbo spectroscopic imaging (FuTSI) were developed and shown to capture the entire $^{19}$F spectrum, albeit with a significant acquisition time penalty [129].

A more straightforward method to image complex $^{19}$F spin systems, in consideration of destructive phase interference, is to acquire the signal before the spins de-phase, as in ultra-short echo time (UTE) imaging [130]. UTE potentially boosts $^{19}$F SNR by capturing an NMR signal before line de-phasing and significant transverse relaxation can occur [109]. Balanced steady-state free precession (SSFP) is a technique in which each gradient pulse within one repetition time (TR) is compensated by a gradient pulse with an opposite polarity, resulting in a single, re-phased magnetization vector [131]. As such, the SSFP sequence retains much of the initial magnetization ($M_0$), which yields a steady-state MR signal with high achievable SNR. Balanced SSFP sequences have been used effectively for imaging mesenchymal cells labeled with the CellSense™ $^{19}$F PFC probe, which has a single resonance peak [132]. To achieve highly sensitive detection of multi-resonant imaging labels like PFOB, a dual-frequency $^{19}$F/$^1$H UTE-balanced SSFP pulse sequence with 3D radial readout was employed on a clinical 3 T scanner to image PFC (Figure 4) [111]. The majority of the PFOB fluorine nuclei (12 of 17) are located in the CF$_2$ resonances within a 1 kHz CS range that can be captured within a 90 µs TE of the UTE-SSFP sequence. This short TE preserves the NMR signal from significant de-phasing and avoids the destructive superposition of these resonances. The SNR gain achieved by constructive addition of the CF$_2$ lines more than compensates for the loss in SNR efficiency imposed by 3D radial sampling (25%) and the free induction decay (FID) readout.

The UTE-SSFP technique offers several benefits for the multinuclear imaging of non-proton agents. When $^{19}$F contrast agents are bound to target tissues, they can exhibit further reduced
T2 relaxation due to decreased molecular motion [113]. The balanced SSFP approach contributes high SNR for imaging labels with unfavorable relaxation conditions for gradient-echo methods due to $M_0$ saturation exhibiting a long T1 and short T2. By altering offset frequency and excitation bandwidth for a particular $^{19}$F line group of interest, UTE-SSFP can be customized to the probe of choice. Furthermore, the UTE-SSFP sequence can be combined with simultaneous dual-nuclei techniques. Once the complex spectral signal is acquired with this sequence, the 3D radial-filled k-space data are directly reconstructed without post-processing, in contrast to CS imaging. The 3D radial dataset offers multi-resolution reconstruction, allowing analysis of the $^{19}$F and $^1$H data at different spatial resolutions as well as the opportunity to motion-correct the non-proton signal with temporal sub-sampling of the $^1$H data [114].

UTE-SSFP may not be ideal for all PFC probes, however. For agents with single resonance peaks, such as PFCE or PFPE, decreased SNR efficiency may result from the 3D radial k-space sampling and FID readout. Furthermore, UTE-SSFP requires that the particular line group selected must occur within a 1–2 kHz bandwidth for appropriate spatial resolution of the 3D radial readout with standard gradient systems. For PFOB, the $^{19}$F line group of interest spans a 1 kHz bandwidth, but other probes can differ. For compounds with fewer $^{19}$F nuclei than typically associated with PFC emulsions, particularly when imaged at higher than current clinical field strengths in order to achieve SNR, alternative approaches to UTE imaging such as zero time echo (ZTE) may be optimal [109]. Regardless, ultrafast imaging capability on modern MR instrumentation has enabled a renaissance in $^{19}$F imaging that was impossible a decade ago.

6 $^{19}$F cell tracking and macrophage labeling

The concepts of tracking cellular fates in vivo following the uptake of PFC emulsions labeled ex vivo or in situ have been well reviewed but deserve some recapitulation, since this concept has progressed from the bench to the clinic within the last several years [93, 99]. Phagocytic uptake of systemically injected PFC nanoparticles is an inherent feature of their natural clearance from the body by the MPS. For in vivo in situ labeling, relatively large volumes of particles are intravenously introduced, whereby engulfment ensues by various subgroups of leukocytes, predominantly monocytes, macrophages, neutrophils, and dendritic cells (DCs). The $^{19}$F-labeled leukocytes, often resident in the spleen, are recruited by cytokines into inflamed areas where their accumulation can be monitored noninvasively via MR. This concept of in situ PFC labeling of macrophages and the MPS organs was appreciated in the early studies detecting $^{19}$F hotspots in rat tumors and abscesses [133] and PFC emulsions were later detected in myocardial infarcts and cancers, although the imaging approaches were not exclusive to $^{19}$F MR and included US and CT [5, 35–37, 134–136]. Furthermore, studies irradiating the spleen to reduce its phagocytic function demonstrated decreased particle uptake and offered early evidence of the organ’s important MPS role in PFC particle clearance [137]. Subsequently, $^{19}$F MRI with in situ cell labeling has been used to monitor inflammation associated with autoimmune disease in experimental allergic encephalomyelitis (EAE) [67], human pancreatic cells [138], ischemic myocardium and the cerebrum [139], LPS-induced pulmonary inflammation [140], allograft rejection [96], neuroinflammatory peripheral nerve disease [141], and collagen-induced arthritis in rodents.
Moreover, these studies point to the qualitative relationship between the severity of the inflammation and the magnitude of the $^{19}$F MRI signal. Indeed, this concept is well established, and is perhaps preferable in some respects to iron-oxide-based cell-tracking techniques. Iron oxides are very sensitive markers of cells, but they tend to reduce soft-tissue resolution due to superparamagnetic bloom artifacts, which are avoided with $^{19}$F. The lack of magnetic artifact allows tissue and cellular boundary image detail to remain.

In many reports, specific cells such as DCs [94] and stem cells [63] have been labeled ex vivo and then injected or implanted in vivo. $^{19}$F imaging has been performed acutely in order to demonstrate the technique and even show the potential for using different PFCs to differentiate cell types simultaneously as well as longitudinally to follow their migration. When labeling cells ex vivo, the specific lineage and $^{19}$F cell-labeling efficiency is known and can be used to improve the biological and quantitative interpretation of the resultant data. In contradistinction, in situ labeling allows the $^{19}$F signal to be qualitatively followed but precludes accurately knowing which cell types are being imaged or quantitatively related to the $^{19}$F signal intensity on spin-density weighted MR techniques.

Recently, Ahrens et al. [98] used PFPE nanoparticles (CS-1000) for $^{19}$F cell-tracking of immunotherapeutic mature DCs in patients with colorectal adenocarcinoma. The PFPE agent used was rigorously tested for acute toxicity, cytotoxicity, and genotoxicity prior to clinical use without adverse effects at 100-fold the clinical dose anticipated. PFPE was incorporated into nonphagocytic cells without adjunctive cationic lipids and without altering the cellular phenotype. It is notable that only viable cells were labeled with PFPE. However, in vivo cell death can liberate the PFC, which may then be engulfed by macrophages, leading to a false positive signal. The same is true of iron oxides, and can be an inherent confounding problem of the technique in general. Post-implantation DCs were noted as “hotspots” at the injection site, and that signal diminished by 50% the next day. This result affirmed that the label cells were injected and, in two patients, the technique allowed the number of cells to be estimated. The further disposition of the cells was not appreciated. A correlation with the lack of response—whether due to an inadequate therapeutic load injected, marked early cell death, DC migration, or an ineffectiveness of the treatment concept—remains an open question. Although this clinical study used rudimentary data-acquisition methods and a suboptimal MRI detector (surface coil) design, it still showed the potential for $^{19}$F imaging efficacy with a clinical scanner. The advancements in coil, pulse sequence design, and motion correction are now better understood and when implemented will likely improve the diagnostic results achieved.

7 $^{19}$F PFC nanoparticle molecular imaging of thrombus

The use of $^{19}$F imaging and PFC nanoparticles for thrombus diagnosis dates back more than a decade. Thrombus is rich in molecular epitopes for targeting, in particular fibrin, thrombin, and in some instances, platelets. Yu et al. [142] demonstrated high-field molecular imaging of fibrin-targeted paramagnetic PFOB nanoparticles using human clot phantoms, and showed not only the $^1$H T1-weighted contrast of PFC particles decorated with surface $\text{Gd}^{3+}$ DTPA-BOA, but also the corresponding $^{19}$F signal. Although the improved $^{19}$F R1/R2...
relaxation enhancement of Gd$^{3+}$ DTPA-BOA in the lipid surfactant was not appreciated at the time, in hindsight it is clear that this factor contributed to the robust $^{19}$F result.

In subsequent studies, the dual imaging proton and the quantitative potential of $^{19}$F imaging and spectroscopy with paramagnetic PFOB nanoparticles was demonstrated at 4.7 T, and was corroborated by proton relaxation rates at 1.5 T and radioactive gadolinium metal using neutron activation analysis [55]. The clinical relevance of this concept was illustrated with ex vivo human carotid endarterectomy for uniquely and quantitatively detecting ruptured plaque (Figure 5). The use of $^{19}$F spectroscopy and imaging for the simultaneous differentiation of two nanoparticle emulsions with PFCE or PFOB cores targeted to fibrin clot phantoms illustrated the potential for noninvasive phenotypic characterization of pathological targets. The underlying proposition was that pathologic differentiation of complex tissues will require multiple biomarkers, and the unique ratio of the receptor expression levels could be used to characterize and diagnose pathology. In this experiment, the PFCE nanoparticles incorporated gadolinium. $^{19}$F images were acquired using steady-state gradient-echo techniques and spectra acquired with volume-selective and nonselective sampling. The imaging used conventional T1-weighted imaging clots with PFCE nanoparticles, which were enhanced as expected with the intensity contrast signal decreasing monotonically with particle concentration. All clots were visualized using wide-bandwidth $^{19}$F imaging while a restricted bandwidth excitation permitted the independent imaging of PFCE or PFOB nanoparticles.

In the coagulation cascade, thrombin represents a principal target of direct and specific anticoagulants, which can be accessed via a thrombin inhibitor (Phe[DP]-Pro -Arg- chloromethylketone, or PPACK) complexed onto colloidal nanoparticles [143]. This theranostic construct was devised as a first-in-class anticoagulant with a prolonged and highly localized therapeutic impact conferred by its multivalent thrombin-absorbing particle surface. In an in vivo acute arterial thrombosis model, PPACK nanoparticles outperformed both heparin and uncomplexed PPACK in inhibiting thrombosis. $^{19}$F MRS (11.7 T) confirmed that the PPACK nanoparticles specifically bound to sites of acute thrombotic injury. The $^{19}$F MRI showed co-localization of particles within an artery. It is of interest that although these thrombin-inhibiting nanoparticles only increased the systemic bleeding time for 10 min, they provided prolonged clot inhibition.

More recently, noninvasive identification of developing thrombi using $^{19}$F MRI and 2-antiplasmin peptide ($\alpha_2$AP)-targeted PFC nanoemulsions was reported [144]. Ligand functionality was achieved under mild coupling conditions using a sterol-based post-insertion technique. Targeted imaging of murine inferior vena cava thrombus using simultaneous acquisition of $^1$H and $^{19}$F MR images at 9.4 T was achieved with excellent SNR and CNR. The $\alpha_2$AP-PFCs construct was also evaluated for the diagnosis of experimentally induced pulmonary thromboembolism. $\alpha_2$AP-PFCs targeted the thrombus as clot formation progressed, but 60 min after thrombus induction, no detectable $^{19}$F signal was appreciated. This result suggests that crosslinking of fibrin by the thrombin-activated factor XIIIa was completed, and points to the utility of $\alpha_2$AP-PFCs for differentiating thrombolytic labile versus drug-resistant thrombus. This therapeutic approach could improve the risk-benefit balance for thrombolytic treatment.
The fluorine-rich core of PFC nanoparticles can also serve as a quantitative reference from which to normalize and characterize chemical exchange saturation transfer (CEST) agents targeted to fibrin clots or other targets [145]. CEST chelates have exchangeable protons (—NH, —OH, etc.) that resonate at a CS that is distinguishable from the bulk water signal. RF pre-pulses applied at the appropriate frequency and power can saturate the exchangeable protons that then transfer into the bulk water pool and reduce the equilibrium magnetization. PFC nanoparticles functionalized with paramagnetic CEST (PARACEST) chelates offer a switchable contrast, which is achieved by adjusting the pulse sequence parameters. This important feature of CEST agents obviates the need for pre- and post-injection images, which is common with most 1H-based molecular imaging contrast probes. Moreover, the newly designed PARACEST PFC nanoparticles produced a CNR of 10 at the clot surface, which helped to address the lack of contrast sensitivity of early PARACEST agents. In addition to lowering the effective detection limit by delivering very large payloads of PARACEST chelates on the PFC nanoparticle surface, the PFC core itself provided a 19F signal for quantitative particle-binding estimation. The simultaneous availability of two unique signatures, 19F and PARACEST, directly indicated the voxel concentration of the PARACEST chelates that were bound. Moreover, when bound to the clot surface, the PARACEST nanoparticles produce more than two-fold higher PARACEST contrast than when free in suspension. This was suggested to be due to reduced nanoparticle mobility and slowed water-exchange kinetics. The increased bound water lifetime lowered the detection limit from 4.13 mmol·L$^{-1}$ for nanoparticles in suspension to 2.30 mmol·L$^{-1}$ for nanoparticles bound to a target. Indeed, CEST and PARACEST agents have evolved from their humble beginnings to become important MR contrast agents [144, 146–178].

8 19F angiogenesis imaging

Angiogenesis is a critical early feature of normal tissues, such as the endometrium, bone growth plates, and wound healing, as well as of pathologies such as rheumatoid arthritis, atherosclerosis, asthma, and cancers. The detection of angiogenesis via molecular imaging of the $\alpha_\nu\beta_3$-integrin expressed by neoendothelial cells requires low nanomolar sensitivity per voxel for detectability. High-resolution 19F imaging of angiogenesis was first used to detect and quantify the neovascularature in a rabbit model of aortic valve disease with $\alpha_\nu\beta_3$-PFC-nanoparticles [70]. Atherosclerotic New Zealand White rabbits were treated with $\alpha_\nu\beta_3$-targeted PFC nanoparticles or untargeted PFC nanoparticles. The excised aortic valve leaflets were thickened and inflamed. 19F MRS at 11.7 T of the valve leaflets from rabbits treated with $\alpha_\nu\beta_3$-targeted PFC nanoparticles had 220% more 19F signal than their counterparts receiving untargeted PFC nanoparticles. Furthermore, in a competitive inhibition treatment group, the valve leaflet 19F signal was reduced by 42%, supporting the specificity of the targeting. In a second cohort of atherosclerotic rabbits, 19F spectroscopy performed at 3 T using a clinical scanner again demonstrated the effectiveness of $\alpha_\nu\beta_3$-targeted PFC nanoparticles for neovascular imaging, which was further corroborated with immunohistochemistry.

Molecular imaging of U87 glioblastoma at 7 T in mice using $\alpha_\nu\beta_3$-PF0B nanoparticles similarly showed concentrations in mice tumors to be greater than in the control, although nonspecific background signal originating in blood at this high-field strength persisted in
this experiment [179]. These imaging results were corroborated by histology and by fluorescence microscopy. Importantly, this was the first $^{19}$F imaging example in brain tumor angiogenesis that was obtained with integrin-targeted PFC nanoparticles. This group later developed polymeric encapsulation of PF0B with an extended circulatory half-life, and then functionalized it with an Arg-Gly-Asp (RGD, an anti-integrin) ligand in order to demonstrate its use for tumor imaging with $^{19}$F as well [180, 181].

As mentioned earlier, angiogenesis is an important constituent of inflammatory pulmonary diseases, such as asthma. Early neovascular expansion in the lungs in patients is very difficult to assess noninvasively, and particularly quantitatively. With the notable exception of significant lung tumors, pulmonary $^1$H MRI of parenchymal disease is challenging due to a paucity of tissue water protons, respiratory motion, and CS artifacts. $^{19}$F/$^1$H MR molecular imaging with $\alpha_{\nu}\beta_3$-targeted PFOB nanoparticles can be used to directly measure neovascularity. To validate the $^{19}$F/$^1$H MRI technique in the lung, an established rat left pulmonary artery ligation (LPAL) model was employed [182]. LPAL induces the bronchial artery vasculature to proliferate into zones of acute inflammatory lung injury, notably surrounding the bronchioles and large vasculature proximal to the ligature [182].

Three days after pulmonary artery ligation, simultaneous $^{19}$F/$^1$H MRI at 3 T was performed following the injection of $\alpha_{\nu}\beta_3$-targeted PFC nanoparticles [183]. The injured rat lung and bronchi had an increased $^{19}$F signal with targeted PFC particles compared to the nontargeted agent (Figure 6). Almost no $^{19}$F signal was appreciated in the control right lungs with targeted or nontargeted PFC nanoparticles. Competitive inhibition of $\alpha_{\nu}\beta_3$-targeted PFC nanoparticles decreased the $^{19}$F angiogenesis signal in the ischemic left lung, a reduction that was not different from the $^{19}$F signal obtained in the nontargeted group (Figure 7). Supporting fluorescent and light microscopy illustrated the heavy nanoparticle decorating of vessel walls in and around the large bronchi and large pulmonary vessels. These results demonstrated that $^{19}$F/$^1$H MR molecular imaging with $\alpha_{\nu}\beta_3$-PFC nanoparticles provided a direct and reproducible readout of neovascularization in the injured lung.

Next, this validated $^{19}$F imaging technique was applied to interrogate the aberrant bronchial neovascularity associated with chronic asthmatic airway as a possible factor contributing to persistent airway wall edema and sustained leukocyte recruitment [184]. The causal relationships between exposure to house dust mites (HDMs) and the development of asthma is well established. Rats were exposed bi-weekly to HDM inhalation and studied after one, two, or three weeks of antigen exposure. The time course of the appearance of increased blood vessels within the airway wall was assessed noninvasively with $^{19}$F MRI and corroborated with quantitative microscopy. A methacholine challenge study was used to assess for hyper-reactive airway response, characteristic of asthma. After three weeks of HDM exposure (six inhalation doses), the number of mature vessels counted within the airway walls of bronchial airways (0.5–3 mm perimeter) increased significantly. These vascular changes were accompanied by increased airway responsiveness to methacholine. However, after only one or two weeks of the HDM challenge, no significant change in functional vessel numbers or methacholine airway reactivity was noted. $^{19}$F/$^1$H MRI at 3 T with $\alpha_{\nu}\beta_3$-targeted PFC nanoparticle infusion established increases in $^{19}$F signal in rat airways after one and two weeks of bi-weekly HDM, revealing the earlier activation of the
process of neovascularization before increased airway hyper-reactivity was appreciated (Figure 8). Moreover, when gross pathological and clinical manifestations were manifest, $^{19}$F molecular imaging showed that the acute neovascular expansion phase had passed.

This use of $^{19}$F/$^1$H for pulmonary imaging is particularly relevant because MRI is not clinically exploited for interrogating diffuse parenchymal lung diseases, yet the prevalence of these pathologies and healthcare costs to treat them are soaring. Although CT is often used to study lung pathology, in general it has a low sensitivity to early disease, where medical management can have the greatest impact. Moreover, for patients dealing with lifetime chronic diseases, serial exposure to ionizing radiation is problematic, particularly for patients who are diagnosed at younger ages. Echocardiography to assess right ventricular (RV) function, morphology, and valvular hemodynamics is often used as a surrogate marker for increasing pulmonary hypertension, but it is imprecise, relatively insensitive, and provides no direct quantification of the spatial extent or distribution of the disease in the lung itself. Indeed, simultaneous $^{19}$F/$^1$H MR molecular imaging at 3 T with the improvements in coils and imaging techniques now offers high potential to address these inflammation-based typically fibrotic diseases when the cadre of new medicants can be useful and optimized to the individual.

9 Conclusions

This introduction to $^{19}$F MRI has illustrated how a concept first considered in the 1970s is now on the verge of clinical relevance in 2015. Improvements in MR instrumentation, coils, and pulse sequences have begun to overcome the fundamental issues that have precluded clinical translation for many years. Whether for cell or targeted molecular imaging or for other applications such as oxygen sensing [185–190], PFC particles are coming to the fore in MR by virtue of their dense fluorine content and relatively bio-inert properties, offering imaging possibilities that take advantage of and complement traditional $^1$H MRI. While more work needs to be done, it seems that a breakthrough application is near, and once that is achieved, the floodgates of applications for these unique nuclei will be open. The only barrier that seems to stand between this technology and its clinical reality is unmitigated will power.

Acknowledgments

This research was supported in whole or part by grants from the National Institutes of Health (CA154737, CA199092, HL122471, HL112518, HL113392, and HHSN26820140042C for Gregory M. Lanza; AR067491, DK102691, and HL073646 for Samuel A. Wickline). We appreciate the further support provided the Barnes-Jewish Research Foundation.

References

1. Holland GN, Bottomley PA, Hinshaw WS. $^{19}$F magnetic resonance imaging. J Magn Reson. 1977; 28(1):133–136.
2. Shimizu M, et al. Tumor imaging with anti-CEA antibody labeled $^{19}$F emulsion. Magn Reson Med. 1987; 5(3):290–295. [PubMed: 3431398]
3. Busse LJ, Pratt RG, Thomas SR. Deconvolution of chemical shift spectra in two- or three-dimensional $^{19}$F MR imaging. J Comput Assist Tomogr. 1988; 12(5):824–835. [PubMed: 3170845]

4. Bottomley PA. Human in vivo NMR spectroscopy in diagnostic medicine: Clinical tool or research probe? Radiology. 1989; 170(1):1–15. [PubMed: 2642336]

5. Mason RP, Antich PP, Babcock EE, Gerberich JL, Nunnally RL. Perfluorocarbon imaging in vivo. A $^{19}$F MRI study in tumor-bearing mice. Magn Reson Imaging. 1989; 7(5):475–485. [PubMed: 2607898]

6. Lee HK, Nalcioglu O, Buxton RB. Correction of chemical-shift artifacts in $^{19}$F imaging of PFOB: A robust signed magnitude method. Magn Reson Med. 1992; 23(2):254–263. [PubMed: 1549040]

7. Meyer KL, Carvlin MI, Mukherji B, Sloviter HA, Joseph PM. Fluorinated blood substitute retention in the rat measured by fluorine-19 magnetic resonance imaging. Invest Radiol. 1992; 27(8):620–627. [PubMed: 1428740]

8. Bachert P. Pharmacokinetics using fluorine NMR in vivo. Prog Nucl Magn Res Sp. 1998; 33(1):1–56.

9. Reid DG, Murphy PS. Fluorine magnetic resonance in vivo. A powerful tool in the study of drug distribution and metabolism. Drug Discov Today. 2008; 13(11–12):473–480. [PubMed: 18549972]

10. Wolf W, Presant CA, Waluch V. $^{19}$F-MRS studies of fluorinated drugs in humans. Adv Drug Deliv Rev. 2000; 41(1):55–74. [PubMed: 10699305]

11. Kaneda MM, Caruthers S, Lanza GM, Wickline SA. Perfluorocarbon nanoemulsions for quantitative molecular imaging and targeted therapeutics. Ann Biomed Eng. 2009; 37(10):1922–1933. [PubMed: 19184435]

12. Kaufman, RJ. Clinical development of perfluorocarbon-based emulsions as red cell substitutes. In: Sjöblom, J., editor. Emulsions and Emulsion Stability. New York: Marcel Dekker, Inc; 1996. p. 343-368.

13. Krafft MP. Fluorocarbons and fluorinated amphiphiles in drug delivery and biomedical research. Adv Drug Deliv Rev. 2001; 47(2–3):209–228. [PubMed: 11311993]

14. Eckmann DM, Swartz MA, Glucksberg MR, Gavriely N, Grothberg JB. Perfluorocarbon induced alterations in pulmonary mechanics. Artif Cells Blood Substit Immobil Biotechnol. 1998; 26(3):259–271. [PubMed: 9635119]

15. Eckmann DM, Swartz MA, Gavriely N, Glucksberg MR, Grothberg JB. Influence of intravenous perfluorocarbon administration on the dynamic behavior of lung surfactant. Artif Cells Blood Substit Immobil Biotechnol. 1998; 26(4):359–366. [PubMed: 9663334]

16. Zhou HF, Chan HW, Wickline SA, Lanza GM, Pham CT. $\alpha_1\beta_3$-targeted nanotherapy suppresses inflammatory arthritis in mice. FASEB J. 2009; 23(9):2978–2985. [PubMed: 19376816]

17. Hampton JC. An electron microscope study of the hepatic uptake and excretion of submicroscopic particles injected into the blood stream and into the bile duct. Acta Anat (Basel). 1958; 32(3):262–291. [PubMed: 13532240]

18. Bulte JWM, Schmieder AH, Keupp J, Caruthers SD, Wickline SA, Lanza GM. MR cholangiography demonstrates unsuspected rapid biliary clearance of nanoparticles in rodents: Implications for clinical translation. Nanomedicine (Lond). 2014; 10(7):1385–1388.

19. Juhlin L. Excretion of intravenously injected solid particles in bile. Acta Physiol Scand. 1960; 49(2–3):224–230. [PubMed: 14408109]

20. Modell JH, Newby EJ, Ruiz BC. Long-term survival of dogs after breathing oxygenated perfluorocarbon liquid. Fed Proc. 1970; 29(5):1731–1736. [PubMed: 5457580]

21. Curtis SE, Peek JT, Kelly DR. Partial liquid breathing with perfluoron improves arterial oxygenation in acute canine lung injury. J Appl Physiol. 1993; 75(6):2696–2702. [PubMed: 8125892]

22. Curtis SE, Tilden SJ, Bradley WE, Cain SM. Effect of continuous rotation on the efficacy of partial liquid (perfluor) breathing in canine acute lung injury. Adv Exp Med Biol. 1994; 361:449–456. [PubMed: 7597969]

23. Bendel-Stenzel EM, Mrozek JD, Bing DR, Meyers PA, Connett JE, Mammel MC. Dynamics of spontaneous breathing during patient-triggered partial liquid ventilation. Pediatr Pulmonol. 1998; 26(5):319–325. [PubMed: 9859900]

Engineering (Beijing). Author manuscript; available in PMC 2016 April 22.
24. Franz AR, Mack C, Reichart J, Pohlandt F, Hummler HD. Preserved spontaneous breathing improves cardiac output during partial liquid ventilation. Am J Respir Crit Care Med. 2001; 164(1):36–42. [PubMed: 11435236]

25. Thome UH, Schulze A, Schnabel R, Franz AR, Pohlandt F, Hummler HD. Partial liquid ventilation in severely surfactant-depleted, spontaneously breathing rabbits supported by proportional assist ventilation. Crit Care Med. 2001; 29(6):1175–1180. [PubMed: 11395598]

26. Geyer RP. “Bloodless” rats through the use of artificial blood substitutes. Fed Proc. 1975; 34(6): 1499–1505. [PubMed: 805063]

27. Riess JG, Le Blanc M. Perfluoro compounds as blood substitutes. Angew Chem Int Ed Engl. 1978; 17(9):621–634. [PubMed: 101099]

28. Mitsuno T, Ohyanagi H, Naito R. Clinical studies of a perfluorochemical whole blood substitute (Fluosol-DA): Summary of 186 cases. Ann Surg. 1982; 195(1):60–69. [PubMed: 7034658]

29. Chang TM, Farmer M, Geyer RP, Moss G. Blood substitutes based on modified hemoglobin and fluorochemicals. ASAIO Trans. 1987; 33(4):819–823. [PubMed: 3426865]

30. Hong F, Shastri KA, Logue GL, Spaulding MB. Complement activation by artificial blood substitute Fluosol: In vitro and in vivo studies. Transfusion. 1991; 31(7):642–647. [PubMed: 1909821]

31. Flaim SF. Pharmacokinetics and side effects of perfluorocarbon-based blood substitutes. Artif Cells Blood Subst Immobil Biotechnol. 1994; 22(4):1043–1054. [PubMed: 7849908]

32. Lowe KC. Perfluorinated blood substitutes and artificial oxygen carriers. Blood Rev. 1999; 13(3):171–184. [PubMed: 10527269]

33. Jacoby C, et al. Probing different perfluorocarbons for in vivo inflammation imaging by $^{19}$F MRI: Image reconstruction, biological half-lives and sensitivity. NMR Biomed. 2014; 27(3):261–271. [PubMed: 24353148]

34. Jacoby C, et al. Visualization of immune cell infiltration in experimental viral myocarditis by $^{19}$F MRI in vivo. MAGMA. 2014; 27(1):101–106. [PubMed: 23824166]

35. Mattrey RF, Scheible FW, Gosink BB, Leopold GR, Long DM, Higgins CB. Perfluoroctylbromide: A liver/spleen-specific and tumor-imaging ultrasound contrast material. Radiology. 1982; 145(3):759–762. [PubMed: 7146409]

36. Mattrey RF, Long DM, Mutter F, Mitten R, Higgins CB. Perfluoroctylbromide: A reticuloendothelial-specific and tumor-imaging agent for computed tomography. Radiology. 1982; 145(3):755–758. [PubMed: 7146408]

37. Mattrey RF, Andre MP. Ultrasonic enhancement of myocardial infarction with perfluorocarbon compounds in dogs. Am J Cardiol. 1984; 54(1):206–210. [PubMed: 6741815]

38. Peck WW, Mattrey RF, Slutsky RA, Higgins CB. Perfluorooctylbromide: Acute hemodynamic effects, in pigs, of intravenous administration compared with the standard ionic contrast media. Invest Radiol. 1984; 19(2):129–132. [PubMed: 6533103]

39. Mattrey RF, et al. Perfluorochemicals as gastrointestinal contrast agents for MR imaging: Preliminary studies in rats and humans. AJR Am J Roentgenol. 1987; 148(6):1259–1263. [PubMed: 3495156]

40. Long DC, Long DM, Riess J, Follana R, Burgan A, Mattrey RF. Preparation and application of highly concentrated perfluoroctylbromide fluorocarbon emulsions. Biomater Artif Cells Artif Organs. 1988; 16(1–3):441–442. [PubMed: 3179479]

41. Mattrey RF. Perfluoroctylbromide: A new contrast agent for CT, sonography, and MR imaging. AJR Am J Roentgenol. 1989; 152(2):247–252. [PubMed: 2643258]

42. Mattrey RF, Nemcek AA Jr, Shelton R, André MP, Mitten RM, Peterson T. In vivo estimation of perfluoroctylbromide concentration in tissues. Invest Radiol. 1990; 25(8):915–921. [PubMed: 2394575]

43. Mattrey RF, Trambert MA, Brown JJ, Bruneton JN, Young SW, Schooley GL. Results of the phase III trials with Imagent GI as an oral magnetic resonance contrast agent. Invest Radiol. 1991; 26(Suppl 1):S65–S66. discussion S71. [PubMed: 1808151]

44. Mattrey RF, Schumacher DJ, Tran HT, Guo Q, Buxton RB. The use of Imagent® BP in diagnostic imaging research and $^{19}$F magnetic resonance for PO$_2$ measurements. Biomater Artif Cells Immobilization Biotechnol. 1992; 20(2–4):917–920. [PubMed: 1391533]
45. Lanza GM, et al. A novel site-targeted ultrasonic contrast agent with broad biomedical application. Circulation. 1996; 94(12):3334–3340. [PubMed: 8989148]
46. Lanza GM, et al. High-frequency ultrasonic detection of thrombi with a targeted contrast system. Ultrasound Med Biol. 1997; 23(6):863–870. [PubMed: 9309990]
47. Lanza GM, et al. In vitro characterization of a novel, tissue-targeted ultrasonic contrast system with acoustic microscopy. J Acoust Soc Am. 1998; 104(6):3665–3672. [PubMed: 9857523]
48. Lanza GM, et al. Enhanced detection of thrombi with a novel fibrin-targeted magnetic resonance imaging agent. Acad Radiol. 1998; 5(Suppl 1):S173–S176. discussion S183–S184. [PubMed: 9561074]
49. Anderson SA, et al. Magnetic resonance contrast enhancement of neovasculature with αvβ3-targeted nanoparticles. Magn Reson Med. 2000; 44(3):433–439. [PubMed: 10975896]
50. Flacke S, et al. Novel MRI contrast agent for molecular imaging of fibrin: Implications for detecting vulnerable plaques. Circulation. 2001; 104(11):1280–1285. [PubMed: 11551880]
51. Lanza GM, et al. Targeted antiproliferative drug delivery to vascular smooth muscle cells with a magnetic resonance imaging nanoparticle contrast agent: Implications for rational therapy of restenosis. Circulation. 2002; 106(22):2842–2847. [PubMed: 12451012]
52. Winter PM, et al. Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel αvβ3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res. 2003; 63(18):5838–5843. [PubMed: 14522907]
53. Winter PM, et al. Molecular imaging of angiogenesis in early-stage atherosclerosis with αvβ3-integrin-targeted nanoparticles. Circulation. 2003; 108(18):2270–2274. [PubMed: 14557370]
54. Morawski AM, et al. Targeted nanoparticles for quantitative imaging of sparse molecular epitopes with MRI. Magn Reson Med. 2004; 51(3):480–486. [PubMed: 15004788]
55. Morawski AM, et al. Quantitative “magnetic resonance immunohistochemistry” with ligand-targeted 19F nanoparticles. Magn Reson Med. 2004; 52(6):1255–1262. [PubMed: 15562481]
56. Schmieder AH, et al. Molecular MR imaging of melanoma angiogenesis with αvβ3-targeted paramagnetic nanoparticles. Magn Reson Med. 2005; 53(3):621–627. [PubMed: 15723405]
57. Winter PM, et al. Molecular imaging of human thrombus with computed tomography. Acad Radiol. 2005; 12(5 Suppl 1):S9–S13. [PubMed: 16106538]
58. Cyrus T, et al. MR three-dimensional molecular imaging of intramural biomarkers with targeted nanoparticles. J Cardiovasc Magn Reson. 2006; 8(3):535–541. [PubMed: 16755843]
59. Winter PM, et al. Endothelial αvβ3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler Thromb Vasc Biol. 2006; 26(9):2103–2109. [PubMed: 16825592]
60. Hu G, et al. Imaging of Vx-2 rabbit tumors with αvβ3-integrin-targeted111In nanoparticles. Int J Cancer. 2007; 120(9):1951–1957. [PubMed: 17278104]
61. Marsh JN, et al. Fibrin-targeted perfluorocarbon nanoparticles for targeted thrombolysis. Nanomedicine (Lond). 2007; 2(4):533–543. [PubMed: 17716136]
62. Neubauer AM, et al. Fluorine cardiovascular magnetic resonance angiography in vivo at 1.5 T with perfluorocarbon nanoparticle contrast agents. J Cardiovasc Magn Reson. 2007; 9(3):565–573. [PubMed: 17365236]
63. Partlow KC, et al. 19F magnetic resonance imaging for stem/progenitor cell tracking with multiple unique perfluorocarbon nanobeacons. FASEB J. 2007; 21(8):1647–1654. [PubMed: 17284484]
64. Cyrus T, et al. Intramural delivery of rapamycin with αvβ3-targeted paramagnetic nanoparticles inhibits stenosis after balloon injury. Arterioscler Thromb Vasc Biol. 2008; 28(5):820–826. [PubMed: 18292395]
65. Lijowski M, et al. High sensitivity: High-resolution SPECT-CT/MR molecular imaging of angiogenesis in the Vx2 model. Invest Radiol. 2009; 44(1):15–22. [PubMed: 18836386]
66. Partlow KC, Lanza GM, Wickline SA. Exploiting lipid raft transport with membrane targeted nanoparticles: A strategy for cytosolic drug delivery. Biomaterials. 2008; 29(23):3367–3375. [PubMed: 18485474]
67. Ruiz-Cabello J, et al. In vivo “hot spot” MR imaging of neural stem cells using fluorinated nanoparticles. Magn Reson Med. 2008; 60(6):1506–1511. [PubMed: 19025893]
68. Schmieder AH, et al. Three-dimensional MR mapping of angiogenesis with α5β1(ανβ3)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model. FASEB J. 2008; 22(12):4179–4189. [PubMed: 18697838]

69. Soman NR, Lanza GM, Heuser JM, Schlesinger PH, Wickline SA. Synthesis and characterization of stable fluorocarbon nanostructures as drug delivery vehicles for cytolytic peptides. Nano Lett. 2008; 8(4):1131–1136. [PubMed: 18302330]

70. Waters EA, Chen J, Allen JS, Zhang H, Lanza GM, Wickline SA. Detection and quantification of angiogenesis in experimental valve disease with integrin-targeted nanoparticles and 19-fluorine MRI/MRS. J Cardiovasc Magn Reson. 2008; 10:43. [PubMed: 18817557]

71. Winter PM, Caruthers SD, Zhang H, Williams TA, Wickline SA. Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis. JACC Cardiovasc Imaging. 2008; 1(5):624–634. [PubMed: 19356492]

72. Winter PM, et al. Minute dosages of αvβ3-targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and development in rabbits. FASEB J. 2008; 22(8):2758–2767. [PubMed: 18362202]

73. Keupp, J.; Caruthers, SD.; Rahmer, J.; Williams, TA.; Wickline, SA.; Lanza, GM. Fluorine-19 MR molecular imaging of angiogenesis on Vx-2 tumors in rabbits using αvβ3-targeted nanoparticles. Proceedings of International Society for Magnetic Resonance in Medicine (ISMRM) 17th Annual Scientific Meeting and Exhibition; Honolulu, HI, USA. 2009; p. 223

74. Soman NR, et al. Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth. J Clin Invest. 2009; 119(9):2830–2842. [PubMed: 19726870]

75. Southworth R, et al. Renal vascular inflammation induced by Western diet in ApoE-null mice quantified by 19F NMR of VCAM-1 targeted nanobeacons. Nanomedicine (Lond). 2009; 5(3):359–367.

76. Cai K, et al. MR molecular imaging of aortic angiogenesis. JACC Cardiovasc Imaging. 2010; 3(8):824–832. [PubMed: 20705262]

77. Kassner A, et al. Assessment of tumor angiogenesis: Dynamic contrast-enhanced MRI with paramagnetic nanoparticles compared with Gd-DTPA in a rabbit Vx-2 tumor model. Contrast Media Mol Imaging. 2010; 5(3):155–161. [PubMed: 20586031]

78. Lanza GM, et al. Theragnostics for tumor and plaque angiogenesis with perfluorocarbon nanoemulsions. Angiogenesis. 2010; 13(2):189–202. [PubMed: 20411320]

79. Marsh JN, et al. A fibrin-specific thrombolytic nanomedicine approach to acute ischemic stroke. Nanomedicine (Lond). 2011; 6(4):605–615. [PubMed: 21506686]

80. Thomas DG, et al. Physicochemical signatures of nanoparticle-dependent complement activation. Comput Sci Discov. 2014; 7(1):015003. [PubMed: 25254068]

81. Pham CT, et al. Variable antibody-dependent activation of complement by functionalized phospholipid nanoparticle surfaces. J Biol Chem. 2011; 286(1):123–130. [PubMed: 21047788]

82. Wang K, et al. Synergy between surface and core entrapped metals in a mixed manganese-gadolinium nanocolloid affords safer MR imaging of sparse biomarkers. Nanomedicine (Lond). 2015; 11(3):601–609.

83. Kedziorek DA, et al. Gene expression profiling reveals early cellular responses to intracellular magnetic labeling with superparamagnetic iron oxide nanoparticles. Magn Reson Med. 2010; 63(4):1031–1043. [PubMed: 20373404]

84. Engberink RD, et al. Magnetic resonance imaging of monocytes labeled with ultrasmall superparamagnetic particles of iron oxide using magnetoelectroporation in an animal model of multiple sclerosis. Mol Imaging. 2010; 9(5):268–277. [PubMed: 20868627]

85. Stuber M, et al. Positive contrast visualization of iron oxide-labeled stem cells using inversion-recovery with ON-resonant water suppression (IRON). Magn Reson Med. 2007; 58(5):1072–1077. [PubMed: 17969120]

86. Bulte JW, Kraitchman DL. Monitoring cell therapy using iron oxide MR contrast agents. Curr Pharm Biotechnol. 2004; 5(6):567–584. [PubMed: 15579045]

87. Frank JA, et al. Magnetic intracellular labeling of mammalian cells by combining (FDA-approved) superparamagnetic iron oxide MR contrast agents and commonly used transfection agents. Acad Radiol. 2002; 9(Suppl 2):S484–S487. [PubMed: 12188316]
88. Bulte JW, Frank JA. Imaging macrophage activity in the brain by using ultrasmall particles of iron oxide. AJNR Am J Neuroradiol. 2000; 21(9):1767–1768. [PubMed: 11039364]

89. Bulte JW, Brooks RA, Moskowitz BM, Bryant LH Jr, Frank JA. T1 and T2 relaxometry of monocrystalline iron oxide nanoparticles (MION-46L): Theory and experiment. Acad Radiol. 1998; 5(Suppl 1):S137–S140. discussion S145–S146. [PubMed: 9561064]

90. Bulte JW, Laughlin PG, Jordan EK, Tran VA, Vymazal J, Frank JA. Tagging of T cells with superparamagnetic iron oxide: Uptake kinetics and relaxometry. Acad Radiol. 1996; 3(Suppl 2):S301–S303. [PubMed: 8796587]

91. Ahrens ET, Flores R, Xu H, Morel PA. In vivo imaging platform for tracking immunotherapeutic cells. Nat Biotechnol. 2005; 23(8):983–987. [PubMed: 16041364]

92. Srinivas M, Morel PA, Ernst LA, Laidlaw DH, Ahrens ET. Fluorine-19 MRI for visualization and quantification of cell migration in a diabetes model. Magn Reson Med. 2007; 58(4):725–734. [PubMed: 1789609]

93. Janjic JM, Ahrens ET. Fluorine-containing nanoemulsions for MRI cell tracking. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2009; 1(5):492–501. [PubMed: 19920872]

94. Helfer BM, et al. Functional assessment of human dendritic cells labeled for in vivo 19F magnetic resonance imaging cell tracking. Cytotherapy. 2010; 12(2):238–250. [PubMed: 20053146]

95. Bonetto F, et al. A novel 19F agent for detection and quantification of human dendritic cells using magnetic resonance imaging. Int J Cancer. 2011; 129(2):365–373. [PubMed: 20839261]

96. Hitchens TK, Ye Q, Eytan DF, Janjic JM, Ahrens ET, Ho C. 19F MRI detection of acute allograft rejection with in vivo perfluorocarbon labeling of immune cells. Magn Reson Med. 2011; 65(4):1144–1153. [PubMed: 21305593]

97. Balducci A, Helfer BM, Ahrens ET, O’Hanlon CF 3rd, Wesa AK. Visualizing arthritic inflammation and therapeutic response by fluorine-19 magnetic resonance imaging (19F MRI). J Inflamm (Lond). 2012; 9(1):24. [PubMed: 22721447]

98. Ahrens ET, Helfer BM, O’Hanlon CF, Schirda C. Clinical cell therapy imaging using a perfluorocarbon tracer and fluorine-19 MRI. Magn Reson Med. 2014; 72(6):1696–1701. [PubMed: 25241945]

99. Ahrens ET, Bulte JW. Tracking immune cells in vivo using magnetic resonance imaging. Nat Rev Immunol. 2013; 13(10):755–763. [PubMed: 24013185]

100. Zhong J, Mills PH, Hitchens TK, Ahrens ET. Accelerated fluorine-19 MRI cell tracking using compressed sensing. Magn Reson Med. 2013; 69(6):1683–1690. [PubMed: 22837054]

101. Hitchens TK, Liu L, Foley LM, Simplaceau V, Ahrens ET, Ho C. Combining perfluorocarbon and superparamagnetic iron-oxide cell labeling for improved and expanded applications of cellular MRI. Magn Reson Med. 2015; 73(1):367–375. [PubMed: 24478194]

102. Janjic JM, Srinivas M, Kadayakkara DKK, Ahrens ET. Self-delivering nanoemulsions for dual fluorine-19 MRI and fluorescence detection. J Am Chem Soc. 2008; 130(9):2832–2841. [PubMed: 18266363]

103. Schlemmer HP, et al. Alterations of intratumoral pharmacokinetics of 5-fluorouracil in head and neck carcinoma during simultaneous radiochemotherapy. Cancer Res. 1999; 59(10):2363–2369. [PubMed: 10344745]

104. Martino R, Gilard V, Desmoulin F, Malet-Martino M. Fluorine-19 or phosphorus-31 NMR spectroscopy: A suitable analytical technique for quantitative in vitro metabolic studies of fluorinated or phosphorylated drugs. J Pharm Biomed Anal. 2005; 38(5):871–891. [PubMed: 16087049]

105. Neubauer AM, et al. Gadolinium-modulated 19F signals from perfluorocarbon nanoparticles as a new strategy for molecular imaging. Magn Reson Med. 2008; 60(5):871–891. [PubMed: 18956457]

106. Harvey P, Kuprov I, Parker D. Lanthanide complexes as paramagnetic probes for 19F magnetic resonance. Eur J Inorg Chem. 2012; 2012(12):2015–2022.

107. de Vries A, et al. Relaxometric studies of gadolinium-functionalized perfluorocarbon nanoparticles for MR imaging. Contrast Media Mol Imaging. 2014; 9(1):83–91. [PubMed: 24470297]
108. Meissner M, Reisert M, Hugger T, Hennig J, von Elverfeldt D, Leupold J. Revealing signal from noisy $^{19}$F MR images by chemical shift artifact correction. Magn Reson Med. 2015; 73(6):2225–2233. [PubMed: 25042821]

109. Schmid F, Höltke C, Parker D, Faber C. Boosting $^{19}$F MRI-SNR efficient detection of paramagnetic contrast agents using ultrafast sequences. Magn Reson Med. 2013; 69(4):1056–1062. [PubMed: 22628001]

110. Goette MJ, Lanza GM, Caruthers SD, Wickline SA. Improved quantitative $^{19}$F MR molecular imaging with flip angle calibration and $B_1$-mapping compensation. J Magn Reson Imaging. 2015; 42(2):488–494. [PubMed: 25425244]

111. Goette MJ, Keupp J, Rahmer J, Lanza GM, Wickline SA, Caruthers SD. Balanced UTE-SSFP for $^{19}$F MR imaging of complex spectra. Magn Reson Med. 2015; 74(2):537–543. [PubMed: 25163853]

112. Rahmer, J., et al. $^{19}$F/$^1$H simultaneous 3D radial imaging of atherosclerotic rabbits using self-navigated respiratory motion compensation. In: Proceedings of International Society for Magnetic Resonance in Medicine (ISMRM) 17th Annual Scientific Meeting and Exhibition; Honolulu, HI, USA. 2009; p. 4611

113. Rahmer, J., et al. Dual resolution simultaneous $^{19}$F/$^1$H in vivo imaging of targeted nanoparticles. Proceedings of International Society for Magnetic Resonance in Medicine (ISMRM) 17th Annual Scientific Meeting and Exhibition; Honolulu, HI, USA. 2009; p. 612

114. Keupp J, et al. Simultaneous dual-nuclei imaging for motion corrected detection and quantification of $^{19}$F imaging agents. Magn Reson Med. 2011; 66(4):1116–1122. [PubMed: 21394779]

115. Otake Y, Soutome Y, Hirata K, Ochi H, Bito Y. Double-tuned radiofrequency coil for $^{19}$F and $^1$H imaging. Magn Reson Med Sci. 2014; 13(3):199–205. [PubMed: 24990464]

116. Ji Y, et al. Eight-channel transceiver RF coil array tailored for $^1$H/$^{19}$F MR of the human knee and fluorinated drugs at 7.0 T. NMR Biomed. 2015; 28(6):726–737. [PubMed: 25916199]

117. Hu L, et al. A generalized strategy for designing $^{19}$F/$^1$H dual-frequency MRI coil for small animal imaging at 4.7 tesla. J Magn Reson Imaging. 2011; 34(1):245–252. [PubMed: 21698714]

118. Hockett FD, et al. Simultaneous dual frequency $^1$H and $^{19}$F open coil imaging of arthritic rabbit knee at 3 T. IEEE Trans Med Imaging. 2011; 30(1):22–27. [PubMed: 20699209]

119. Muftuler LT, Gulsen G, Sezen KD, Nalcioglu O. Automatic tuned MRI RF coil for multinuclear imaging of small animals at 3 T. J Magn Reson. 2002; 155(1):39–44. [PubMed: 11945031]

120. Mazurkewitz, P.; Leussler, C.; Keupp, J.; Schaeffter, T. A double-resonant $^{19}$F/$^1$H transmit/receive solenoid coil for MRI. Proceedings of International Society for Magnetic Resonance in Medicine (ISMRM) 14th Scientific Meeting and Exhibition; Seattle, WA, USA. 2006; p. 2596

121. Ballon D, Graham MC, Miodownik S, Koutcher JA. A 64 MHz half-birdcage resonator for clinical imaging. J Magn Reson. 1990; 90(1):131–140.

122. Jin J, Magin RL, Shen G, Perkins T. A simple method to incorporate the effects of an RF shield into RF resonator analysis for MRI applications. IEEE Trans Biomed Eng. 1995; 42(8):840–843. [PubMed: 7642198]

123. Goette, MJ.; Lanza, GM.; Wickline, SA.; Caruthers, SD. Quantitative molecular imaging of fluorinated agents: $^{19}$F flip angle calibration using $^1$H power settings. Proceedings of International Society for Magnetic Resonance in Medicine (ISMRM) 20th Annual Scientific Meeting and Exhibition; Melbourne, Victoria, Australia. 2012; p. 1655

124. Mastropietro A, et al. Optimization of rapid acquisition with relaxation enhancement (RARE) pulse sequence parameters for $^{19}$F-MRI studies. J Magn Reson Imaging. 2014; 40(1):162–170. [PubMed: 25050436]

125. Reeder SB, Herzka DA, McVeigh ER. Signal-to-noise ratio behavior of steady-state free precession. Magn Reson Med. 2004; 52(1):123–130. [PubMed: 15236375]

126. Yu J, et al. Optimization of scan parameters in pulmonary partial pressure oxygen measurement by hyperpolarized $^3$He MRI. Magn Reson Med. 2008; 59(1):124–131. [PubMed: 18050348]

127. Keupp, J.; Mazurkewitz, PC.; Gräßlin, I.; Schaeffter, T. Simultaneous $^{19}$F and $^1$H imaging on a clinical 3 T MR scanner. Proceedings of International Society for Magnetic Resonance in Medicine (ISMRM) 14th Scientific Meeting and Exhibition; Seattle, WA, USA. 2006; p. 102
128. Keupp, J.; Wickline, SA.; Lanza, GM.; Caruthers, SD. Hadamard-type pulse-phase encoding for imaging of multi-resonant fluorine-19 nanoparticles in targeted molecular MRI. Proceedings of International Society for Magnetic Resonance in Medicine (ISMRM) 18th Annual Scientific Meeting and Exhibition; Stockholm, Sweden. 2010; p. 982

129. Lamerichs, R., et al. In vivo 3D $^{19}$F fast spectroscopic imaging (F-uTSI) of angiogenesis on Vx-2 tumors in rabbits using targeted perfluorocarbon emulsions. In. Proceedings of International Society for Magnetic Resonance in Medicine (ISMRM) 18th Annual Scientific Meeting and Exhibition; Stockholm, Sweden. 2010; p. 457

130. Rahmer J, Börnert P, Groen J, Bos C. Three-dimensional radial ultra-short echo-time imaging with $T_2$ adapted sampling. Magn Reson Med. 2006; 55(5):1075–1082. [PubMed: 16538604]

131. Scheffler K, Lehnhardt S. Principles and applications of balanced SSFP techniques. Eur Radiol. 2003; 13(11):2409–2418. [PubMed: 12928954]

132. Ribot EJ, Gaudet JM, Chen Y, Gilbert KM, Foster PJ. In vivo MR detection of fluoride-labeled human MSC using the bSSFP sequence. Int J Nanomedicine. 2014; 9(1):1731–1739. [PubMed: 24748787]

133. Longmaid HE 3rd, et al. In vivo $^{19}$F NMR imaging of liver, tumor, and abscess in rats: Preliminary results. Invest Radiol. 1985; 20(2):141–145. [PubMed: 3988465]

134. Mattrey RF, et al. Specific enhancement of intra-abdominal abscesses with perfluorocetyl bromide for CT imaging. Invest Radiol. 1984; 19(5):438–446. [PubMed: 6511250]

135. Sartoris DJ, et al. Perfluorocetyl bromide as a contrast agent for computed tomographic imaging of septic and aseptic arthritis. Invest Radiol. 1986; 21(1):49–55. [PubMed: 3943957]

136. Ratner AV, et al. Detection of tumors with $^{19}$F magnetic resonance imaging. Invest Radiol. 1988; 23(5):361–364. [PubMed: 3384616]

137. Ratner AV, Muller HH, Bradley-Simpson B, Hirst D, Pitts W, Young SW. Detection of acute radiation damage to the spleen in mice by using fluoride-19 MR imaging. AJR Am J Roentgenol. 1988; 151(3):477–480. [PubMed: 3261505]

138. Barnett BP, et al. Use of perfluorocarbon nanoparticles for non-invasive multimodal cell tracking of human pancreatic islets. Contrast Media Mol Imaging. 2011; 6(4):251–259. [PubMed: 21861285]

139. Flögel U, et al. In vivo monitoring of inflammation after cardiac and cerebral ischemia by fluorine magnetic resonance imaging. Circulation. 2008; 118(2):140–148. [PubMed: 18574049]

140. Ebner B, et al. Early assessment of pulmonary inflammation by $^{19}$F MRI in vivo. Circ Cardiovasc Imaging. 2010; 3(2):202–210. [PubMed: 20061515]

141. Vasudeva K, et al. Imaging neuroinflammation in vivo in a neuropathic pain rat model with near-infrared fluorescence and $^{19}$F magnetic resonance. PLoS ONE. 2014; 9(2):e90589. [PubMed: 24587398]

142. Yu X, et al. High-resolution MRI characterization of human thrombus using a novel fibrin-targeted paramagnetic nanoparticle contrast agent. Magn Reson Med. 2000; 44(6):867–872. [PubMed: 11108623]

143. Myerson J, He L, Lanza G, Tollefsen D, Wickline S. Thrombin-inhibiting perfluorocarbon nanoparticles provide a novel strategy for the treatment and magnetic resonance imaging of acute thrombosis. J Thromb Haemost. 2011; 9(7):1292–1300. [PubMed: 21605330]

144. Gilad AA, et al. Artificial reporter gene providing MRI contrast based on proton exchange. Nat Biotechnol. 2007; 25(2):217–219. [PubMed: 17259977]

145. Winter PM, et al. Molecular imaging of angiogenic therapy in peripheral vascular disease with $\alpha_v\beta_3$-integrin-targeted nanoparticles. Magn Reson Med. 2010; 64(2):369–376. [PubMed: 20665780]

146. Vinogradov E, Sherry AD, Lenkinski RE. CEST: From basic principles to applications, challenges and opportunities. J Magn Reson. 2013; 229:155–172. [PubMed: 23273841]

147. Vinogradov E, Soesbe TC, Balsha JC, Sherry AD, Lenkinski RE. pCEST: Positive contrast using Chemical Exchange Saturation Transfer. J Magn Reson. 2012; 215:64–73. [PubMed: 22237630]

148. Ratnakar SJ, Viswanathan S, Kovacs Z, Jindal AK, Green KN, Sherry AD. Europium(III) DOTA-tetraamide complexes as redox-active MRI sensors. J Am Chem Soc. 2012; 134(13):5798–5800. [PubMed: 22420507]
149. Khemtong C, et al. Off-resonance saturation MRI of superparamagnetic nanoprobes: Theoretical models and experimental validations. J Magn Reson. 2011; 209(1):53–60. [PubMed: 21277813]

150. Coman D, Kiefer GE, Rothman DL, Sherry AD, Hyder F. A lanthanide complex with dual biosensing properties: CEST (chemical exchange saturation transfer) and BIRDS (biosensor imaging of redundant deviation in shifts) with europium DOTA-tetraglycinate. NMR Biomed. 2011; 24(10):1216–1225. [PubMed: 22020775]

151. Viswanathan S, Ratnakar SJ, Green KN, Kovacs Z, De León-Rodríguez LM, Sherry AD. Multi-frequency PARACEST agents based on europium(III)-DOTA-tetraamide ligands. Angew Chem Int Ed Engl. 2009; 48(49):9330–9333. [PubMed: 19894248]

152. Khemtong C, et al. In vivo off-resonance saturation magnetic resonance imaging of αβ3-targeted superparamagnetic nanoparticles. Cancer Res. 2009; 69(4):1651–1658. [PubMed: 19190328]

153. Zhao JM, et al. Size-induced enhancement of chemical exchange saturation transfer (CEST) contrast in liposomes. J Am Chem Soc. 2008; 130(15):5178–5184. [PubMed: 18361490]

154. Pasha A, Tircsó G, Benyó ET, Brücher E, Sherry AD. Synthesis and characterization of DOTA-(amide)4 derivatives: Equilibrium and kinetic behavior of their lanthanide(III) complexes. Eur J Inorg Chem. 2007; 2007(27):4340–4349. [PubMed: 19802361]

155. Vinogradov E, Zhang S, Lubag A, Balschi JA, Sherry AD, Lenkinski RE. On-resonance low B1 pulses for imaging of the effects of PARACEST agents. J Magn Reson. 2005; 176(1):54–63. [PubMed: 15979362]

156. Di Bari L, Pescitelli G, Sherry AD, Woods M. Structural and chiroptical properties of the two coordination isomers of YbDOTA-type complexes. Inorg Chem. 2005; 44(23):8391–8398. [PubMed: 16270977]

157. Woods M, et al. Synthesis, relaxometric and photophysical properties of a new pH-responsive MRI contrast agent: The effect of other ligating groups on dissociation of a p-nitrophenolic pendant arm. J Am Chem Soc. 2004; 126(30):9248–9256. [PubMed: 15281814]

158. Zhang S, Merritt M, Woessner DE, Lenkinski RE, Sherry AD. PARACEST agents: Modulating MRI contrast via water proton exchange. Acc Chem Res. 2003; 36(10):783–790. [PubMed: 14567712]

159. Zhang S, Wu K, Sherry AD. Gd3+ complexes with slowly exchanging bound-water molecules may offer advantages in the design of responsive MR agents. Invest Radiol. 2001; 36(2):82–86. [PubMed: 11224755]

160. Vandsburger M, et al. Cardio-chemical exchange saturation transfer magnetic resonance imaging reveals molecular signatures of endogenous fibrosis and exogenous contrast media. Circ Cardiovasc Imaging. 2015; 8(1):e002180. [PubMed: 25503999]

161. Rancan G, Delli Castelli D, Aime S. MRI CEST at 1 T with large μeff Ln3+ complexes Tm3+-HPDO3A: An efficient MRI pH reporter. Magn Reson Med. 2015 in press.

162. Longo DL, Sun PZ, Consolino L, Michelotti FC, Uggeri F, Aime S. A general MRI-CEST ratiometric approach for pH imaging: Demonstration of in vivo pH mapping with iobitridol. J Am Chem Soc. 2014; 136(41):14333–14336. [PubMed: 25238643]

163. Terreno E, et al. Gadolinium-doped LipoCEST agents: A potential novel class of dual 1H-MRI probes. Chem Commun (Camb). 2011; 47(16):4667–4669. [PubMed: 21409237]

164. Terreno E, et al. Methods for an improved detection of the MRI-CEST effect. Contrast Media Mol Imaging. 2009; 4(5):237–247. [PubMed: 19839029]

165. Terreno E, Delli Castelli D, Violante E, Sanders HM, Sommerdijk NA, Aime S. Osmotically shrunken LIPOCEST agents: An innovative class of magnetic resonance imaging contrast media based on chemical exchange saturation transfer. Chemistry. 2009; 15(6):1440–1448. [PubMed: 19115311]

166. Terreno E, et al. First ex-vivo MRI co-localization of two LIPOCEST agents. Contrast Media Mol Imaging. 2008; 3(1):38–43. [PubMed: 18335476]

167. Terreno E, et al. Highly shifted LIPOCEST agents based on the encapsulation of neutral polynuclear paramagnetic shift reagents. Chem Commun (Camb). 2008; (5):600–602. [PubMed: 18209802]
168. Aime S, Delli Castelli D, Terreno E. Highly sensitive MRI chemical exchange saturation transfer agents using liposomes. Angew Chem Int Ed Engl. 2005; 44(34):5513–5515. [PubMed: 16052647]
169. Aime S, Carrera C, Delli Castelli D, Genniatti Crich S, Terreno E. Tunable imaging of cells labeled with MRI-PARACEST agents. Angew Chem Int Ed Engl. 2005; 44(12):1813–1815. [PubMed: 15723362]
170. Aime S, Delli Castelli D, Fedeli F, Terreno E. A paramagnetic MRI-CEST agent responsive to lactate concentration. J Am Chem Soc. 2002; 124(32):9364–9365. [PubMed: 12167018]
171. Song X, et al. Multi-echo length and offset VARied saturation (MeLOVARS) method for improved CEST imaging. Magn Reson Med. 2015; 73(2):488–496. [PubMed: 25516490]
172. Bar-Shir A, Yadav NN, Gilad AA, van Zijl PC, McMahon MT, Bulte JW. Single $^{19}$F probe for simultaneous detection of multiple metal ions using miCEST MRI. J Am Chem Soc. 2015; 137(1):78–81. [PubMed: 25523816]
173. Chan KW, Liu G, van Zijl PC, Bulte JW, McMahon MT. Magnetization transfer contrast MRI for non-invasive assessment of innate and adaptive immune responses against alginate-encapsulated cells. Biomaterials. 2014; 35(27):7811–7818. [PubMed: 24930848]
174. Song X, et al. CEST phase mapping using a length and offset varied saturation (LOVARS) scheme. Magn Reson Med. 2012; 68(4):1074–1086. [PubMed: 22246684]
175. Liu G, et al. Monitoring enzyme activity using a diamagnetic chemical exchange saturation transfer magnetic resonance imaging contrast agent. J Am Chem Soc. 2011; 133(41):16326–16329. [PubMed: 21919523]
176. McMahon MT, Gilad AA, DeLiso MA, Cromer Berman SM, Bulte JW, van Zijl PC. New “multicolor” polypeptide diamagnetic chemical exchange saturation transfer (DIACEST) contrast agents for MRI. Magn Reson Med. 2008; 60(4):803–812. [PubMed: 18816830]
177. McMahon MT, Gilad AA, Zhou J, Sun PZ, Bulte JW, van Zijl PC. Quantifying exchange rates in chemical exchange saturation transfer agents using the saturation time and saturation power dependencies of the magnetization transfer effect on the magnetic resonance imaging signal (QUEST and QUESP): Ph calibration for poly-L-lysine and a starburst dendrimer. Magn Reson Med. 2006; 55(4):836–847. [PubMed: 16506187]
178. Snoussi K, Bulte JW, Guéron M, van Zijl PC. Sensitive CEST agents based on nucleic acid imino proton exchange: Detection of poly(rU) and of a dendrimer-poly(rU) model for nucleic acid delivery and pharmacology. Magn Reson Med. 2003; 49(6):998–1005. [PubMed: 12768576]
179. Giraudau C, et al. A new paradigm for high-sensitivity $^{19}$F magnetic resonance imaging of perfluorooctylbromide. Magn Reson Med. 2010; 63(4):1119–1124. [PubMed: 20373415]
180. Diou O, et al. RGD decoration of PEGylated polyester nanocapsules of perfluorooctyl bromide for tumor imaging: Influence of pre or post-functionalization on capsule morphology. Eur J Pharm Biopharm. 2014; 87(1):170–177. [PubMed: 24333400]
181. Diou O, et al. Long-circulating perfluorooctyl bromide nanocapsules for tumor imaging by $^{19}$FMR Imaging. Biomaterials. 2012; 33(22):5593–5602. [PubMed: 22575831]
182. Mitzner W, Lee W, Georgakopoulos D, Wagner E. Angiogenesis in the mouse lung. Am J Pathol. 2000; 157(1):93–101. [PubMed: 10880380]
183. Schmieder AH, et al. Characterization of early neovascular response to acute lung ischemia using simultaneous $^{19}$F/$^{1}$H MR molecular imaging. Angiogenesis. 2014; 17(1):51–60. [PubMed: 23918207]
184. Wagner EM, et al. Angiogenesis and airway reactivity in asthmatic Brown Norway rats. Angiogenesis. 2015; 18(1):1–11. [PubMed: 25149641]
185. Nöth U, Gröhn P, Jork A, Zimmermann U, Haase A, Lutz J. $^{19}$F-MRI in vivo determination of the partial oxygen pressure in perfluorocarbon-loaded alginate capsules implanted into the peritoneal cavity and different tissues. Magn Reson Med. 1999; 42(6):1039–1047. [PubMed: 10571925]
186. Mason RP, Jeffrey FM, Malloy CR, Babcock EE, Antich PP. A non-invasive assessment of myocardial oxygen tension: $^{19}$F NMR spectroscopy of sequestered perfluorocarbon emulsion. Magn Reson Med. 1992; 27(2):310–317. [PubMed: 1334204]
187. Goh F, Long R Jr, Simpson N, Sambanis A. Dual perfluorocarbon method to noninvasively monitor dissolved oxygen concentration in tissue engineered constructs in vitro and in vivo. Biotechnol Prog. 2011; 27(4):1115–1125. [PubMed: 21608139]

188. Goh F, Sambanis A. In vivo noninvasive monitoring of dissolved oxygen concentration within an implanted tissue-engineered pancreatic construct. Tissue Eng Part C Methods. 2011; 17(9):887–894. [PubMed: 21486202]

189. Hu L, Chen J, Yang X, Caruthers SD, Lanza GM, Wickline SA. Rapid quantification of oxygen tension in blood flow with a fluorine nanoparticle reporter and a novel blood flow-enhanced-saturation-recovery sequence. Magn Reson Med. 2013; 70(1):176–183. [PubMed: 22915328]

190. Lemaire L, et al. Perfluorocarbon-loaded lipid nanocapsules as oxygen sensors for tumor tissue pO2 assessment. Eur J Pharm Biopharm. 2013; 84(3):479–486. [PubMed: 23352843]
Figure 1. The dual-frequency coil is conceptualized as two separate LCR resonators ($L_1, C_1, R_1$) and ($L_2, C_2, R_2$) electrically coupled via capacitor $C_3$.

(a) The equivalent circuit diagram; (b) the impedance magnitude output of a SPICE simulation of two capacitively coupled resonators. $^{19}$F is 120.43 MHz and $^1$H is 127.49 MHz at 3 T. Reproduced with permission from Ref. [118].
Figure 2.
(a) Photograph of completed dual-frequency coil and supporting electronics. The six-leg (five-loop) coil structure is shown in the upper left portion of the image. (b) High-resolution $^1$H image of an arthritic rabbit knee, highlighting anatomic features. (c) Spectral lines corresponding to the measured fluorine resonance from PFCE emulsion and trifluoracetic acid (TFA) reference standard. Simultaneously acquired (d) $^1$H and (e) $^{19}$F images of the rabbit knee post injection of the PFCE emulsion. Reproduced with permission from Ref. [118].
Figure 3.
(a) Circuit design of a $^{19}F$/H dual-frequency actively decoupled transmit-only saddle coil for a mouse image at 4.7 T. (b) S11 of actively decoupled dual-frequency saddle coil when switched on and off. (c, d) Normalized $B_1$ field along the diameter and axis of the actively decoupled dual-frequency saddle coil when switched on and off. Reproduced with permission from Ref. [117].
Figure 4. A simultaneous 3D $^{19}$F/$^1$H UTE-SSFP pulse sequence
It consists of simultaneous $^{19}$F/$^1$H RF excitation and subsequent FID acquisition at an ultra-short echo time, using balanced gradients $(m, m_r)$ with a Wong-type radial readout trajectory. Reproduced with permission from Ref. [111].
Figure 5. Proton and fluorine images of a carotid endarterectomy specimen obtained at 4.7 T (independently) and fused

Note that the fluorine pixels superimposed on the T1-weighted contrast image confirm and quantify the fibrin-specific signal. Also note that some regions of apparent T1 brightness are not aligned with the fluorine signal, and are most likely not derived from the paramagnetic nanoparticle. (Bright spots do not necessarily indicate a contrast agent.) Reproduced with permission from Ref. [55].
Figure 6. Comparison of left-right lung signal in day 3 LPAL rats and sham-operated rats, administered nontargeted, $\alpha_v\beta_3$-targeted, or competitive-inhibited $\alpha_v\beta_3$-targeted PFC nanoparticles after two hours.

LPAL rats receiving $\alpha_v\beta_3$-targeted nanoparticles had the greatest $^{19}$F left lung signal compared to the nontargeted PFC particles ($P = 0.005$). Competitive inhibition with $\alpha_v\beta_3$-targeted oil nanoparticles decreased the lung $^{19}$F signal ($P = 0.0001$). The $^{19}$F signal in sham-operated control rats was also greatly decreased ($P = 0.002$). Reproduced with permission from Ref. [183].
Figure 7. Whole-body $^{19}$F/$^1$H images of a rat thorax and abdomen two hours after the injection of $\alpha$,$\beta$$_3$-targeted or nontargeted (NT) PFC nanoparticles (green)

(a) Coronal plane of the rat following $\alpha$,$\beta$$_3$-targeted nanoparticles, showing accumulation in the left lung adjacent to the heart, and reticuloendothelial (RES) clearance of particles in the liver and spleen. Little signal was detected in the right lung. (b) Sagittal view of the targeted nanoparticle accumulation in the left lung. (c) Transverse view at the level of the heart, showing bound nanoparticles in the left but not in the right lung. (d) Coronal plane of the rat following NT-nanoparticles, showing no visual accumulation in the injured left lung adjacent to the heart, but with significant RES clearance of particles into the liver and spleen. (e, f) Sagittal and transverse views of the rat thorax following NT-nanoparticles showing negligible accumulation in the injured lung. No signal is appreciated in the right lung. In all these images, no off-target contrast was appreciated in the surrounding musculature. The $^1$H image shown above was obtained at higher resolution using a clinical 3 T scanner for higher thoracic anatomical clarity. Yellow arrows indicate examples of ringing artifact recognized in this particular MRI sequence, which are common to high-signal areas (i.e., liver and spleen). Reproduced with permission from Ref. [183].
Figure 8.
(a, b) $^1$H/$^{19}$F dual simultaneous MR molecular imaging scans of PBS and HDM rats two weeks after the onset of sensitization using $\alpha_\beta_3$-targeted PFC nanoparticles. Note that uniform $^{19}$F weighting was applied to all images from all animals, and voxel size was set to the original acquisition of $1.25 \text{ mm} \times 1.25 \text{ mm} \times 1.25 \text{ mm}$. (c) The overall three-week effect of HDM sensitization on total $^{19}$F signal in arbitrary units compared to PBS controls ($*P = 0.007$). (d, e) Rhodamine labeled $\alpha_\beta_3$-targeted PFC nanoparticles in frozen sections of large bronchi of PBS and HDM rats two weeks after the onset of sensitization. (f) Sub-analysis weekly comparisons of the effect of HDM sensitization versus the PBS controls, showing early induction of angiogenesis by week one with a statistical peak difference observed after two weeks between PBS and HDM treatment ($P = 0.05$), which was followed by a
neovascular decline in the magnitude and treatment difference at three weeks. Reproduced with permission from Ref. [184].